What is Regenxbio Inc (RGNX) stock price today?

Regenxbio Inc (RGNX) currently trades at $8.97 per share. The stock has a market capitalization of $452.17M and a P/E ratio of —x.

Is RGNX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Regenxbio Inc has a Smart Value Score of 46/100 (Grade C), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Regenxbio Inc's revenue and earnings?

Regenxbio Inc has trailing twelve-month (TTM) revenue of $170.44M with profit margins of -113.70%. Earnings per share (EPS) is $-3.76.

Is RGNX stock overvalued or undervalued?

Based on our DCF model, Regenxbio Inc's intrinsic value is $14.17, representing a margin of safety of 41.07%. The stock currently trades at a P/E of —x.

RGNX

Regenxbio Inc

NASDAQ: RGNX · HEALTHCARE · BIOTECHNOLOGY

$8.97

+6.79% today

Updated 2026-04-30

Market cap

$452.17M

P/E ratio

—

P/S ratio

2.65x

EPS (TTM)

$-3.76

Dividend yield

—

52W range

$7 – $16

Volume

0.8M

Market cap

$452.17M

P/E ratio

—

P/S ratio

2.65x

EPS (TTM)

$-3.76

Dividend yield

—

52W range

$7 – $16

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: C

Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

8.3

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$27.82

+210.14%

12-Month target

—

Intrinsic (DCF)

$14.17

Margin of safety

+41.07%

4 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 43.00% QoQ

+ 41.07% below intrinsic value

Risks

- Thin margins at -113.70%

- Negative free cash flow $-52.80M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$112.72M	$90.24M	$83.33M	$170.44M	$170.44M
Net income	$-280.32M	$-263.49M	$-227.10M	$-193.88M	$-67.15M
EPS	—	—	—	—	$-3.76
Free cash flow	$-238.21M	$-228.37M	$-175.56M	$-126.38M	$-52.80M
Profit margin	-248.68%	-291.99%	-272.54%	-113.75%	-113.70%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RGNX	$452.17M	46	7.3	2.0	8.3	5.0	+41.07%	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Regenxbio Inc trades at $8.97. Our Smart Value Score of 46/100 indicates the stock is fair. TTM revenue stands at $170.44M. with profit margins at -113.70%. Our DCF model estimates intrinsic value at $14.17.

Frequently asked questions

What is Regenxbio Inc's stock price?

Regenxbio Inc (RGNX) trades at $8.97.

Is Regenxbio Inc overvalued?

Smart Value Score 46/100 (Grade C, Sell). DCF value $14.17.

What is the price target of Regenxbio Inc (RGNX)?

The analyst target price is $27.82, representing +210.1% upside from the current price of $8.97.

What is the intrinsic value of Regenxbio Inc (RGNX)?

Based on our DCF model, intrinsic value is $14.17, a +41.1% margin of safety versus $8.97.

What is Regenxbio Inc's revenue?

TTM revenue is $170.44M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio2.65x

ROE-107.00%

Beta1.13

50D MA$8.70

200D MA$10.53

Shares out0.05B

Float0.04B

Short ratio—

Avg volume0.8M

Performance

1 week-7.71%

1 month+10.94%

3 months-21.71%

YTD-40.14%

1 year—

3 years—

5 years—

Compare

RGNX vs LLY →RGNX vs JNJ →RGNX vs ABBV →Stock screener →